Additionally, our recent clinical results show efficacy of enzalutamide plus fulvestrant therapy compared to fulvestrant alone in the neoadjuvant setting for large primary ER+ BC (52) and for some patients with heavily pretreated ER+ BC (55). The gene discussed is ESR1; the disease is breast cancer.